category,datetime,headline,id,image,related,source,summary,url
company,1769208303,Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know,138229907,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.",https://finnhub.io/api/news?id=92d5c0cb66e70aa0422bcf8374d34aaabfde0c7e0089b41f509d2db853dadf54
company,1769195194,Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly,138229280,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16. ... Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly",https://finnhub.io/api/news?id=1daf049c39fbca9e13fe510e58893d7091cd7bf100ab398e1397b132a9c7fddd
company,1769191500,Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?,138228445,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115
company,1769189603,NVIDIA (NVDA) Invests $150 million in Baseten,138226851,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"NVIDIA Corporation (NASDAQ:NVDA) is one of the Best Quantum Computing Stocks to Buy for 2026. On January 20, WSJ reported that the company is investing $150 million in Baseten, a startup that specializes in AI inference. Baseten has raised $300 million at a $5 billion valuation. This deal demonstrates NVIDIA Corporation (NASDAQ:NVDA)’s aggressive push into […]",https://finnhub.io/api/news?id=20a6c90e91eec1d7a8f44f607439ef250d224eff418ac93a76db9fd229908176
company,1769187970,Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues,138226854,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.,https://finnhub.io/api/news?id=97e0bf4727146630488a61fbc2a12c1107643a4a665d0b5b152bcdb3a106d6a3
company,1769183447,Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position,138225571,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.,https://finnhub.io/api/news?id=0500deeddc3b02f7dc6c01d8256686e1c90592c248a6f948fe626bc0776e4f31
company,1769182904,Novo Nordisk: This Run Is Just Getting Started,138229027,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536,LLY,SeekingAlpha,"Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock here.",https://finnhub.io/api/news?id=699e0e89bd929ba43ec087a27b212bfea84c4fdd3517b973abdb13f10c31709c
company,1769182600,VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion,138226911,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option on the market’s continued growth. Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) combined represented nearly one-third of the ETF. If you believe the ... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",https://finnhub.io/api/news?id=f09384037823b06108c46f090642fce1be1e770587275b0673a3629195b85fd8
company,1769181634,"Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",138225574,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.,https://finnhub.io/api/news?id=5e5e9f46e903ac4621eb5c757a13a2b5d321d541bf765f86717e45a3dff8394e
company,1769177126,"Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",138225630,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",https://finnhub.io/api/news?id=2943bd566d2221e385656b80777f10322bb6bf0107b1bac9a18b61ae608a5743
company,1769175360,Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings,138225631,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",https://finnhub.io/api/news?id=9b077c59e797e4ea01bcd54334d200de183be16426ec55c70fc8dec1828a99b0
company,1769164200,"Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",138223428,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,This biotech has candidates in late-stage clinical development.,https://finnhub.io/api/news?id=8c3bf3e2acb462c864ef416e1d3ed64c88e4eae0fb8448aa245f51e36eb85359
company,1769151601,"What obesity drugmakers see next in the market: More pills, easier access and drug combinations",138226467,https://image.cnbcfm.com/api/v1/image/108253253-1768511651216-gettyimages-2255813292-WEGOVY_PILLS.jpeg?v=1769106872&w=1920&h=1080,LLY,CNBC,"CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco. ",https://finnhub.io/api/news?id=e69a89e18c4ccf186242eb8613a7743e95e35683e2a2e2fc6f3f0e07e1f5616c
company,1769149800,"AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",138222072,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772
company,1769142777,2 Mega-Cap Stocks to Target This Week and 1 We Find Risky,138229281,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",https://finnhub.io/api/news?id=32293175dda2b41fc17783b5022d0171c335141121c063c8b6c2051457538805
